Halozyme Therapeutics, Inc. $HALO Shares Acquired by Allworth Financial LP

Allworth Financial LP increased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 322.5% during the third quarter, Holdings Channel.com reports. The fund owned 39,736 shares of the biopharmaceutical company’s stock after acquiring an additional 30,331 shares during the quarter. Allworth Financial LP’s holdings in Halozyme Therapeutics were worth $2,914,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. IFP Advisors Inc grew its position in Halozyme Therapeutics by 17.8% in the third quarter. IFP Advisors Inc now owns 5,206 shares of the biopharmaceutical company’s stock worth $382,000 after buying an additional 785 shares during the last quarter. Swiss Life Asset Management Ltd bought a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth $426,000. CIBC Private Wealth Group LLC boosted its stake in shares of Halozyme Therapeutics by 12.8% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 2,891 shares of the biopharmaceutical company’s stock worth $212,000 after acquiring an additional 329 shares in the last quarter. Coldstream Capital Management Inc. grew its holdings in shares of Halozyme Therapeutics by 1.9% in the 3rd quarter. Coldstream Capital Management Inc. now owns 8,914 shares of the biopharmaceutical company’s stock worth $654,000 after acquiring an additional 165 shares during the last quarter. Finally, Danske Bank A S acquired a new position in shares of Halozyme Therapeutics in the 3rd quarter worth $4,604,000. 97.79% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

HALO has been the subject of several analyst reports. The Goldman Sachs Group reaffirmed a “sell” rating and set a $56.00 target price on shares of Halozyme Therapeutics in a report on Thursday, December 4th. Wall Street Zen cut Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Saturday, February 21st. TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Benchmark upped their price objective on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Finally, HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, January 29th. Six analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics has an average rating of “Hold” and a consensus price target of $78.56.

Insider Activity

In related news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $76.12, for a total transaction of $1,522,400.00. Following the transaction, the chief executive officer directly owned 708,719 shares of the company’s stock, valued at approximately $53,947,690.28. The trade was a 2.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Cortney Caudill sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $67.80, for a total transaction of $1,356,000.00. Following the completion of the transaction, the chief operating officer owned 14,366 shares in the company, valued at approximately $974,014.80. This represents a 58.20% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 90,857 shares of company stock worth $6,500,287 in the last 90 days. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $63.43 on Friday. Halozyme Therapeutics, Inc. has a 12 month low of $47.50 and a 12 month high of $82.22. The company has a quick ratio of 3.66, a current ratio of 4.66 and a debt-to-equity ratio of 43.89. The stock has a market cap of $7.49 billion, a PE ratio of 25.47, a price-to-earnings-growth ratio of 0.26 and a beta of 0.98. The business has a fifty day simple moving average of $71.53 and a 200-day simple moving average of $70.20.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of $1.92 by ($2.16). The business had revenue of $451.77 million for the quarter, compared to analyst estimates of $446.13 million. Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. During the same period in the previous year, the firm posted $1.26 earnings per share. The firm’s quarterly revenue was up 51.6% on a year-over-year basis. On average, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.